Comments
MSN Laboratories has entered into a license agreement with Defence Research & Development Establishment (DRDE) and Institute of Nuclear Medicine and Allied Sciences (INMAS) — establishments of the Defence Research & Development Organisation (DRDO) — for the manufacturing, distribution and marketing of 2- Deoxy-D-Glucose (2-DG) in India.
Hyderabad-based MSN Labs will be launching the 2-DG as a twice-a-day product in sachet form under the brand name MSN 2D, in strength of 2.34 g.
Developed by DRDO, 2-DG has been granted permission by Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe Covid-19 patients.
MSN is now conducting clinical trials with investigational drugs like Aviptadil on severe hospitalised patients and with Molnupiravir on mild and moderate Covid patients, according to a release.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.